# POU2AF3

## Overview
POU2AF3, also known as POU class 2 homeobox associating factor 3, is a gene that encodes a transcriptional coactivator protein involved in the regulation of gene expression. The protein plays a critical role in modulating chromatin accessibility and activating downstream signaling pathways, particularly in the context of cancer. It is notably involved in small cell lung cancer (SCLC) where it forms a complex with the POU2F3 transcription factor, contributing to oncogenic signaling in specific SCLC subtypes (He2024Targeting). Additionally, POU2AF3 is implicated in other cancers, such as colorectal cancer and thymic carcinomas, where its expression and interactions are altered, influencing tumor development and progression (Yamada2023Thymic; Rajasekaran2023Genetic). The protein's involvement in these processes makes it a potential target for therapeutic interventions in cancer treatment.

## Clinical Significance
POU2AF3, also known as POU class 2 homeobox associating factor 3, has been implicated in various cancers due to alterations in its expression and interactions. In small cell lung cancer (SCLC), POU2AF3 is part of the POU2F3-POU2AF2/3 transcription factor complex, which is crucial for the POU2F3-driven subtype of SCLC (SCLC-P). This subtype shows a dependency on the mSWI/SNF chromatin remodeling complex, and targeting this complex with specific degraders has shown potential in reducing tumor growth in preclinical models (He2024Targeting).

In thymic carcinomas, POU2AF3, along with POU2F3 and POU2AF2, is significantly upregulated compared to thymomas, suggesting a role in the pathology of these tumors (Yamada2023Thymic). Additionally, POU2AF3 is involved in EWSR1/FUS::POU2AF3 sarcomas, aggressive neoplasms that often recur and metastasize, particularly affecting the head and neck region (Skálová2024Molecular).

These findings highlight the clinical significance of POU2AF3 in cancer, where its altered expression and interactions contribute to tumor development and progression, offering potential targets for therapeutic intervention.

## Interactions
POU2AF3, also known as COLCA2, is a transcriptional coactivator that interacts with various proteins and nucleic acids to regulate gene expression. In small cell lung cancer (SCLC), POU2AF3 interacts with the POU2F3 transcription factor, forming a complex that is crucial for modulating chromatin accessibility and activating downstream signaling pathways. This interaction is facilitated by the mSWI/SNF chromatin remodeling complex, which is essential for the oncogenic signaling in POU2F3-driven SCLC subtypes (He2024Targeting).

POU2AF3 also physically interacts with C11orf53, another transcriptional coactivator, in SCLC. This interaction is important for the regulation of genes critical for tuft cell-like SCLC, as demonstrated by co-immunoprecipitation experiments (Zhou2022Selective). In the context of colorectal cancer, POU2AF3 is associated with genetic variations at the 11q23.1 locus, which affect its expression and are linked to cancer risk. This suggests a role in transcriptional regulation in colonic tuft cells (Rajasekaran2023Genetic).

In thymic carcinomas, POU2AF3 is significantly upregulated and is thought to contribute to the differentiation and identity loss of epithelial cells, indicating its involvement in the transcriptional regulation of these cancer types (Yamada2023Thymic).


## References


[1. (Skálová2024Molecular) Alena Skálová, Martina Bradová, Michael Michal, Elaheh Mosaieby, Natálie Klubíčková, Tomáš Vaněček, and Ilmo Leivo. Molecular pathology in diagnosis and prognostication of head and neck tumors. Virchows Archiv, 484(2):215–231, January 2024. URL: http://dx.doi.org/10.1007/s00428-023-03731-2, doi:10.1007/s00428-023-03731-2. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00428-023-03731-2)

[2. (Yamada2023Thymic) Yosuke Yamada, Kosuke Iwane, Yuki Nakanishi, and Hironori Haga. Thymic carcinoma: unraveling neuroendocrine differentiation and epithelial cell identity loss. Cancers, 16(1):115, December 2023. URL: http://dx.doi.org/10.3390/cancers16010115, doi:10.3390/cancers16010115. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16010115)

3. (Rajasekaran2023Genetic) Genetic variation at 11q23.1 confers colorectal cancer risk by dysregulation of colonic tuft cell transcriptional activatorPOU2AF2. This article has 1 citations.

4. (He2024Targeting) Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies. This article has 3 citations.

[5. (Zhou2022Selective) Chen Zhou, Hui Huang, Yunyi Wang, Erdem Sendinc, and Yang Shi. Selective regulation of tuft cell-like small cell lung cancer by novel transcriptional co-activators c11orf53 and colca2. Cell Discovery, October 2022. URL: http://dx.doi.org/10.1038/s41421-022-00470-7, doi:10.1038/s41421-022-00470-7. This article has 12 citations.](https://doi.org/10.1038/s41421-022-00470-7)